PMID- 37453929
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230901
IS  - 1613-2246 (Electronic)
IS  - 0021-5155 (Linking)
VI  - 67
IP  - 5
DP  - 2023 Sep
TI  - Efficacy of azithromycin hydrate ophthalmic solution for treatment of internal 
      hordeolum and meibomitis with or without phlyctenular keratitis.
PG  - 565-569
LID - 10.1007/s10384-023-01010-w [doi]
AB  - PURPOSE: To evaluate the efficacy of azithromycin hydrate ophthalmic solution for 
      the treatment of internal hordeolum and meibomitis with or without phlyctenular 
      keratitis. STUDY DESIGN: Retrospective study. METHODS: Patients diagnosed with 
      internal hordeolum or meibomitis were prescribed azithromycin hydrate ophthalmic 
      solution twice daily for 2 days and then once daily for 12 days. Depending on the 
      presence of meibomitis-related keratoconjunctivitis (MRKC), we further divided 
      the patients with meibomitis into three subgroups: meibomitis alone (non-MRKC 
      group), meibomitis with non-phlyctenular MRKC (non-phlyctenular group), and 
      meibomitis with phlyctenular MRKC (phlyctenular group). Inflammatory findings 
      (eyelid redness and conjunctival hyperemia) were scored before and after 
      treatment. Some patients also underwent culture testing fluids discharged by the 
      meibomian gland orifices. RESULTS: Three patients (3 eyes) had internal hordeolum 
      and 16 patients (16 eyes) had meibomitis. After treatment, the inflammatory 
      findings disappeared in all eyes with internal hordeolum. Among the patients with 
      meibomitis, three eyes were in the non-MRKC, six in the non-phlyctenular, and 
      seven in the phlyctenular group. The inflammatory findings were significantly 
      improved only in the phlyctenular group. Among seven eyes with positive culture 
      results, Cutibacterium acnes was detected in five, and treatment improved the 
      inflammatory findings in all of these eyes. CONCLUSION: Azithromycin hydrate 
      ophthalmic solution is effective for the treatment of inflammatory meibomian 
      gland diseases, including internal hordeolum and meibomitis. In particular, the 
      agent is highly efficient in patients with phlyctenular MRKC.
CI  - (c) 2023. Japanese Ophthalmological Society.
FAU - Shimizu, Yurie
AU  - Shimizu Y
AD  - Department of Ophthalmology and Visual Science, Hiroshima University Graduate 
      School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 
      734-8551, Japan.
FAU - Shinji, Koichiro
AU  - Shinji K
AD  - Department of Ophthalmology and Visual Science, Hiroshima University Graduate 
      School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 
      734-8551, Japan.
FAU - Mitoma, Kaori
AU  - Mitoma K
AD  - Department of Ophthalmology and Visual Science, Hiroshima University Graduate 
      School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 
      734-8551, Japan.
FAU - Kiuchi, Yoshiaki
AU  - Kiuchi Y
AD  - Department of Ophthalmology and Visual Science, Hiroshima University Graduate 
      School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 
      734-8551, Japan.
FAU - Chikama, Taiichiro
AU  - Chikama T
AUID- ORCID: 0000-0003-4001-678X
AD  - Department of Ophthalmology and Visual Science, Hiroshima University Graduate 
      School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 
      734-8551, Japan. chikama@hiroshima-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20230716
PL  - Japan
TA  - Jpn J Ophthalmol
JT  - Japanese journal of ophthalmology
JID - 0044652
RN  - 83905-01-5 (Azithromycin)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Humans
MH  - Azithromycin
MH  - *Hordeolum/drug therapy
MH  - *Meibomitis
MH  - *Blepharitis/complications/diagnosis/drug therapy
MH  - Ophthalmic Solutions
MH  - Retrospective Studies
MH  - *Keratitis/diagnosis/drug therapy
MH  - *Keratoconjunctivitis
MH  - Inflammation
MH  - Meibomian Glands
MH  - Anti-Bacterial Agents
OTO - NOTNLM
OT  - Azithromycin
OT  - Cutibacterium acnes
OT  - Meibomian gland dysfunction
OT  - Meibomitis
OT  - hordeolum
EDAT- 2023/07/16 01:06
MHDA- 2023/09/01 06:43
CRDT- 2023/07/15 23:02
PHST- 2022/12/02 00:00 [received]
PHST- 2023/06/14 00:00 [accepted]
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/07/16 01:06 [pubmed]
PHST- 2023/07/15 23:02 [entrez]
AID - 10.1007/s10384-023-01010-w [pii]
AID - 10.1007/s10384-023-01010-w [doi]
PST - ppublish
SO  - Jpn J Ophthalmol. 2023 Sep;67(5):565-569. doi: 10.1007/s10384-023-01010-w. Epub 
      2023 Jul 16.